{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:45Z","timestamp":1787002665622,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce their toxicity. In this study, we compared the conditioning protocol of fludarabine with melphalan 140\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (FluMel) with conditioning protocols based on this same backbone but with an additional alkylating agent i.e., either fludarabine\/BCNU (also known as carmustine)\/melphalan (FBM), or fludarabine\/thiotepa\/melphalan (FTM) 110\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . We included 1272 adult patients (FluMel,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091002; FBM\/FTM,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009270) with acute myeloid leukemia (AML) with intermediate\/poor cytogenetic risk in first complete remission (CR) from the registry of the EBMT Acute Leukemia Working Party. Despite patients in the FBM\/FTM group were older (64.1 years vs. 59.8 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and had a worse Karnofsky performance score (KPS\u2009&lt;\u200990, 33% vs. 24%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003), they showed a better overall survival (OS) (2\u2009y OS: 68.3% vs. 58.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and less non-relapse mortality (NRM) (2\u2009y NRM: 15.8% vs. 22.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) compared to patients treated with FluMel. No significant differences were observed in relapse incidence (RI) (2\u2009y RI: 24.9% vs. 23.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.62). In conclusion, the addition of a second alkylating agent (BCNU\/carmustine or thiotepa) to FluMel as FBM\/FTM conditioning, improves OS in AML patients in first CR with intermediate\/poor risk cytogenetics after allo-HCT.\n                  <\/jats:p>","DOI":"10.1038\/s41409-023-02150-w","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T23:27:38Z","timestamp":1701473258000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of fludarabine\/melphalan (FluMel) with fludarabine\/melphalan\/BCNU or thiotepa (FBM\/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation \u2013 a registry study on behalf of the EBMT Acute Leukemia Working Party"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jes\u00fas","family":"Duque-Afonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Ngoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-6678","authenticated-orcid":false,"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-0795","authenticated-orcid":false,"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orchard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-8067","authenticated-orcid":false,"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-3476","authenticated-orcid":false,"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-9366","authenticated-orcid":false,"given":"Keith M. O.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gadisseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"2150_CR1","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","volume":"105","author":"N Granot","year":"2020","unstructured":"Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105:2716\u201329.","journal-title":"Haematologica"},{"key":"2150_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood.2019003662","volume":"135","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449\u201352.","journal-title":"Blood"},{"key":"2150_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","volume":"2","author":"M Eapen","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2:2095\u2013103.","journal-title":"Blood Adv"},{"key":"2150_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/cncr.29163","volume":"121","author":"F Baron","year":"2015","unstructured":"Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, et al. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2015;121:1048\u201355.","journal-title":"Cancer"},{"key":"2150_CR6","doi-asserted-by":"publisher","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","volume":"27","author":"B Oran","year":"2021","unstructured":"Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transpl Cell Ther. 2021;27:921.e1\u2013921.e10.","journal-title":"Transpl Cell Ther"},{"key":"2150_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41409-022-01646-1","volume":"57","author":"J Duque-Afonso","year":"2022","unstructured":"Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT acute leukemia working party. Bone Marrow Transpl. 2022;57:1269\u201376.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.bmt.1702512","volume":"26","author":"R W\u00e4sch","year":"2000","unstructured":"W\u00e4sch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transpl. 2000;26:243\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","volume":"21","author":"H Bertz","year":"2003","unstructured":"Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480\u20134.","journal-title":"J Clin Oncol"},{"key":"2150_CR10","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1182\/blood-2005-01-0196","volume":"105","author":"A Spyridonidis","year":"2005","unstructured":"Spyridonidis A, Bertz H, Ihorst G, Gr\u00fcllich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood. 2005;105:4147\u20138.","journal-title":"Blood"},{"key":"2150_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","volume":"112","author":"R Marks","year":"2008","unstructured":"Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112:415\u201325.","journal-title":"Blood"},{"key":"2150_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bmt.2009.189","volume":"45","author":"SO Ciurea","year":"2010","unstructured":"Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transpl. 2010;45:429\u201336.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3109\/10428194.2011.631159","volume":"53","author":"SO Ciurea","year":"2012","unstructured":"Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, et al. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012;53:901\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2150_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/10428190601186150","volume":"48","author":"I Majolino","year":"2007","unstructured":"Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scim\u00e8 R, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma. 2007;48:759\u201366.","journal-title":"Leuk Lymphoma"},{"key":"2150_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.bbmt.2018.06.024","volume":"24","author":"J Duque-Afonso","year":"2018","unstructured":"Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, W\u00e4sch R, Bertz H, et al. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transpl. 2018;24:2277\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2150_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41409-020-0986-2","volume":"56","author":"J Duque-Afonso","year":"2021","unstructured":"Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, W\u00e4sch R, Bertz H, et al. Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2021;56:110\u201320.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2150_CR18","doi-asserted-by":"crossref","unstructured":"Nagler A, Shimoni A Conditioning. In: Carreras E, Dufour C, Mohty M, Kr\u00f6ger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies 2019. 7th edition. Cham (CH): Springer. Chapter 13.","DOI":"10.1007\/978-3-030-02278-5_13"},{"key":"2150_CR19","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la C\u00e1mara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651\u201364.","journal-title":"Bone Marrow Transplant"},{"key":"2150_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2991\/chi.k.210731.001","volume":"3","author":"F Saraceni","year":"2021","unstructured":"Saraceni F, Scortechini I, Fiorentini A, Dubbini MV, Mancini G, Federici I, et al. Conditioning regimens for frail patients with acute leukemia undergoing allogeneic stem cell transplant: how to strike gently. Clin Hematol Int. 2021;3:153\u201360.","journal-title":"Clin Hematol Int"},{"key":"2150_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"2150_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transpl. 2002;8:468\u201376.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2150_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857\u201364.","journal-title":"Blood"},{"key":"2150_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ajh.26620","volume":"97","author":"DW Beelen","year":"2022","unstructured":"Beelen DW, Stelljes M, Rem\u00e9nyi P, Wagner-Drouet EM, Dreger P, Bethge W, et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97:1023\u201334.","journal-title":"Am J Hematol"},{"key":"2150_CR25","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia. 2007;21:2109\u201316.","journal-title":"Leukemia"},{"key":"2150_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2141.2008.07385.x","volume":"143","author":"ME Bernardo","year":"2008","unstructured":"Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143:548\u201351.","journal-title":"Br J Haematol"},{"key":"2150_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","volume":"120","author":"ME Bernardo","year":"2012","unstructured":"Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120:473\u20136.","journal-title":"Blood"},{"key":"2150_CR28","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41409-022-01777-5","volume":"57","author":"J Finke","year":"2022","unstructured":"Finke J, Schmoor C, Stelljes M, Burchert A, Dreger P, Hegenbart U, et al. Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial. Bone Marrow Transpl. 2022;57:1664\u201370.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2012.13","volume":"47","author":"J Sanz","year":"2012","unstructured":"Sanz J, Boluda JC, Mart\u00edn C, Gonz\u00e1lez M, Ferr\u00e1 C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287\u201393.","journal-title":"Bone Marrow Transpl"},{"key":"2150_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","volume":"121","author":"P Di Bartolomeo","year":"2013","unstructured":"Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849\u201357.","journal-title":"Blood"},{"key":"2150_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;19:117\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2150_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","volume":"26","author":"F Sora","year":"2020","unstructured":"Sora F, Grazia CD, Chiusolo P, Raiola AM, Bregante S, Mordini N. et al. Allogeneic hemopoietic stem cell transplants in patients with Acute Myeloid Leukemia (AML) prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transpl. 2020;26:698\u2013703.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2150_CR33","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.18632\/oncotarget.23273","volume":"9","author":"F Saraceni","year":"2017","unstructured":"Saraceni F, Labopin M, Hamladji RM, Mufti G, Soci\u00e9 G, Shimoni A, et al. Acute leukemia working party of the European society for Blood and Marrow Transplantation (EBMT). Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2017;9:3379\u201393.","journal-title":"Oncotarget"},{"key":"2150_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768\u201378.","journal-title":"J Clin Oncol"},{"key":"2150_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","volume":"127","author":"RA Marsh","year":"2016","unstructured":"Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127:503\u201312.","journal-title":"Blood"},{"key":"2150_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H, Spyridonidis A, W\u00e4sch R, Gr\u00fcllich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transpl. 2009;15:1563\u201370.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02150-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T12:03:36Z","timestamp":1707307416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-02150-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests with the publication of this article. JD-A has received speaker\u2019s honoraria from Roche, Amgen, AstraZeneca, Riemser, Lilly, Ipsen and Sobi and travel support from Gilead and Sobi. JF has received research support and speaker\u2019s honoraria from Medac, Neovii, and Riemser. JAS declares advisory board for Medac, and speaker fees from Novartis, Mallinckrodt, Gilead and Jazz. CCrad declares consulting\/speakers board fees for Abbvie, JAZZ and Medac.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the general assembly of the ALWP of the EBMT.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient authorization was performed via informed consent to include their data in the EBMT registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}